David Nierengarten
Stock Analyst at Wedbush
(4.35)
# 354
Out of 5,090 analysts
209
Total ratings
52.35%
Success rate
17.32%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Reiterates: Outperform | $25 | $13.69 | +82.62% | 2 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $880 → $1,000 | $901.17 | +10.97% | 23 | Nov 14, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $9 → $7 | $9.61 | -27.16% | 11 | Nov 7, 2025 | |
| FATE Fate Therapeutics | Upgrades: Outperform | $5 → $7 | $1.08 | +548.15% | 16 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $90 → $110 | $93.29 | +17.91% | 4 | Oct 17, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $45 → $70 | $44.41 | +57.62% | 14 | Oct 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $38 → $44 | $41.67 | +5.59% | 4 | Oct 13, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $8.55 | -29.82% | 11 | Oct 13, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $109.60 | +4.93% | 6 | Sep 8, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $3.10 | +29.03% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $17.30 | +50.29% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $9.85 | +123.35% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 | $5.36 | +30.60% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $8.18 | -2.20% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.40 | +358.33% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $12.11 | +122.96% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $19.76 | +67.00% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $8.66 | +130.95% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $18.20 | +70.33% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $76.75 | +17.26% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $45.02 | +4.40% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $11.00 | +81.82% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $30.84 | +29.70% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $33.45 | +34.53% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.08 | +825.93% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $3.36 | +435.71% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $38.77 | -74.21% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.74 | +220.86% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $27.09 | +110.41% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $27.78 | +530.06% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.97 | +16,735.02% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $5.75 | +943.48% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.55 | +151.66% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $36.38 | +106.16% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.28 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.07 | - | 3 | Nov 20, 2017 |
BridgeBio Oncology Therapeutics
Nov 25, 2025
Reiterates: Outperform
Price Target: $25
Current: $13.69
Upside: +82.62%
argenx SE
Nov 14, 2025
Maintains: Outperform
Price Target: $880 → $1,000
Current: $901.17
Upside: +10.97%
Intellia Therapeutics
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $9.61
Upside: -27.16%
Fate Therapeutics
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.08
Upside: +548.15%
Disc Medicine
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $93.29
Upside: +17.91%
AnaptysBio
Oct 15, 2025
Maintains: Outperform
Price Target: $45 → $70
Current: $44.41
Upside: +57.62%
Kiniksa Pharmaceuticals International,
Oct 13, 2025
Maintains: Outperform
Price Target: $38 → $44
Current: $41.67
Upside: +5.59%
Nuvation Bio
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $8.55
Upside: -29.82%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $109.60
Upside: +4.93%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $3.10
Upside: +29.03%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $17.30
Upside: +50.29%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $9.85
Upside: +123.35%
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $5.36
Upside: +30.60%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $8.18
Upside: -2.20%
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.40
Upside: +358.33%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $12.11
Upside: +122.96%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $19.76
Upside: +67.00%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $8.66
Upside: +130.95%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $18.20
Upside: +70.33%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $76.75
Upside: +17.26%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $45.02
Upside: +4.40%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $11.00
Upside: +81.82%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $30.84
Upside: +29.70%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $33.45
Upside: +34.53%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.08
Upside: +825.93%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $3.36
Upside: +435.71%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $38.77
Upside: -74.21%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.74
Upside: +220.86%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $27.09
Upside: +110.41%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $27.78
Upside: +530.06%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.97
Upside: +16,735.02%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $5.75
Upside: +943.48%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.55
Upside: +151.66%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $36.38
Upside: +106.16%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.28
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $11.07
Upside: -